Stratifying by time to diagnosis revealed a slightly stronger negative association between NF‐κB expression and prostate cancer risk (OR for the highest quartile =0.33; 95% CI =0.13–0.80; p = 0.01) in the case‐control pairs with longer follow‐up. Here, NFKB1 is linked to prostate carcinoma.